Oncology Today with Dr Neil Love

Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Samuel Klempner from Massachusetts General Hospital in Boston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, and Dr John Strickler from Duke University in Durham, North Carolina, review relevant data supporting immunotherapy for patients with gastroesophageal cancers and recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.CME information and select publications here.

Dr Nikhil I Khushalani from Moffitt Cancer Center in Tampa, Florida, Dr Soo J Park from the UC San Diego Moores Cancer Center in California, Dr Vishal Anil Patel from the GW Cancer Center in Washington, DC, and Dr Evan Wuthrick, also from Moffitt Cancer Center, discusses recent updates on available and novel treatment strategies for nonmelanoma skin cancers.CME information and select publications here.

Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.

Prof Karim Fizazi, an academic oncologist focused on genitourinary cancers, and Dr Daniel George, a prostate cancer clinical investigator at Duke, discuss AKT inhibition and PTEN deficiency in metastatic prostate cancer. They cover biomarker testing methods, rationale for AKT targeting, trial results including CAPItello-281, toxicity management, timing of therapy, and clinical integration of AKT inhibitors.

Professor Giuseppe Curigliano, oncology professor with international trial experience; Dr Hope S Rugo, medical oncologist experienced in breast cancer therapeutics; Dr Marie E McDonnell, endocrinologist specializing in diabetes in cancer patients. They discuss hyperglycemia linked to PI3K/AKT/PTEN inhibitors. Topics include continuous glucose monitoring, steroid-related spikes, timing and incidence of drug-induced hyperglycemia, and practical monitoring plus management strategies.

Dr Jacqueline T Brown, urologic medical oncologist who presents real metastatic urothelial bladder cancer cases. Dr Matthew Milowsky, medical oncologist who interprets clinical evidence and management strategies. They discuss enfortumab vedotin plus pembrolizumab use and duration, managing neuropathy and dose adjustments, brain metastases and local versus systemic approaches, ctDNA, FGFR3/HER2 biomarkers, and sequencing targeted therapies.

Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer.CME information and select publications here.

Prof Andrea Necchi, urothelial clinical investigator focused on novel intravesical systems like TAR‑200. Dr Shilpa Gupta, clinician-researcher in muscle-invasive disease and perioperative systemic therapy. Dr Matthew D Galsky, medical oncologist expert in ctDNA and perioperative trials. They discuss intravesical innovations, PD‑1 plus BCG strategies and sequencing, perioperative EV‑pembro data, and ctDNA‑guided adjuvant decision making.

Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, Dr John Strickler from Duke University in Durham, North Carolina, and moderator Dr Samuel Klempner from Massachusetts General Hospital in Boston review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.CME information and select publications here.

Dr Paul G Richardson, a Dana-Farber myeloma specialist known for leading trials of novel agents, explains CELMoDs and how they more potently target cereblon to degrade Ikaros and Aiolos. He compares newer CELMoDs to older IMiDs. He reviews clinical activity, impressive combos with proteasome inhibitors and antibodies, implications for extramedullary and CNS disease, safety and near-term regulatory outlook.